Medicus Pharma Ltd (MDCX) Stock Price, Quote & News

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus P...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 610 636 0184

Website: medicuspharma.com

Address:

300 Conshohocken State Road, Suite 200, West Conshohocken, United States

Sum_guy_69 Sep. 10 at 12:59 AM

$OCGN $MDCX 🤑🤑🤑

0 · Reply

ThebullishWick Sep. 9 at 11:26 PM

Ticker SGLY could be the next low float hidden monster market sends. -SGLY recently announced a strategic pivot toward AI infrastructure. -Low borrow/600% CTB/Massive book value near $17! $IRD $BIAF $PMN $MDCX :)/.

0 · Reply

Bolnoi Sep. 9 at 10:53 PM

$MDCX r/S and I’ll enter heavy.

0 · Reply

Deng42 Sep. 9 at 8:15 PM

$MDCX patience

0 · Reply

Proecadguy Sep. 9 at 7:53 PM

$MDCX

0 · Reply

Bullishhhalways Sep. 9 at 7:11 PM

$MDCX seems it’s going to crash, don’t disappoint us🤣

1 · Reply

FawkTrading Sep. 9 at 6:40 PM

Rode $SCNX for a small gain today. Continued scaling out of $MERC only holding a small lottery position. Will circle back depending on news. Still in $MDCX AND $FNGR …. I see a light at the end of the tunnel.

0 · Reply

spivak1976 Sep. 9 at 6:22 PM

$MDCX think that’s it people. Could spiral down farther. Will need more news. That news for the partnership was definitely not that amazing. phiser basically leased them one of their old drugs to sell for them for an extremely high dollar. If the drug was that great Phser would not have pulled it off the shelf to begin with.

0 · Reply

Cullousus Sep. 9 at 6:10 PM

$MDCX seems like r/s before a major run occurs i hope im wrong for shareholders sake.

0 · Reply

Steelcurtain04 Sep. 9 at 5:34 PM

$MDCX little humor while we wait

0 · Reply

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

2026-07-28T11:12:13.000Z - 6 weeks ago

Medicus Pharma initiated with a Buy at Alliance Global

2026-07-27T13:10:48.000Z - 6 weeks ago

Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study

Jul 27, 2026, 8:17 AM EDT - 6 weeks ago

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

2026-07-16T11:40:11.000Z - 7 weeks ago

Medicus Pharma receives FDA feedback, IRB approval for Teverelix study

Jul 16, 2026, 7:30 AM EDT - 7 weeks ago

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Jun 22, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

2026-06-15T11:51:23.000Z - 2 months ago

Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA

Jun 15, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Jun 11, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

UAE

2026-06-08T11:37:41.000Z - 3 months ago

Medicus Pharma submits substantial modification application through EU CTIS

Jun 8, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

2026-06-03T13:37:23.000Z - 3 months ago

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma meets with lawmakers to support SkinJect designations

2026-04-27T13:31:02.000Z - 4 months ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

2026-03-18T11:52:25.000Z - 5 months ago

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

Mar 18, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

2026-03-16T11:50:31.000Z - 5 months ago

Medicus Pharma announces SkinJect Phase 2 KOL update

Mar 16, 2026, 7:30 AM EDT - 5 months ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Mar 10, 2026, 7:30 AM EDT - 6 months ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 3, 2026, 7:30 AM EST - 6 months ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

Feb 12, 2026, 7:30 AM EST - 6 months ago

Medicus Pharma on Bloomberg World

Feb 10, 2026, 7:30 AM EST - 7 months ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Jan 23, 2026, 7:30 AM EST - 7 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 22, 2026, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 20, 2026, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Jan 12, 2026, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 5, 2026, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Dec 22, 2025, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 15, 2025, 7:30 AM EST - 8 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 9 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 14, 2025, 5:00 PM EST - 9 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 13, 2025, 7:30 AM EST - 10 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 29, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 22, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 14, 2025, 8:07 AM EDT - 11 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sum_guy_69 Sep. 10 at 12:59 AM

$OCGN $MDCX 🤑🤑🤑

0 · Reply

ThebullishWick Sep. 9 at 11:26 PM

0 · Reply

Bolnoi Sep. 9 at 10:53 PM

$MDCX r/S and I’ll enter heavy.

0 · Reply

Deng42 Sep. 9 at 8:15 PM

$MDCX patience

0 · Reply

Proecadguy Sep. 9 at 7:53 PM

$MDCX

0 · Reply

Bullishhhalways Sep. 9 at 7:11 PM

$MDCX seems it’s going to crash, don’t disappoint us🤣

1 · Reply

FawkTrading Sep. 9 at 6:40 PM

0 · Reply

spivak1976 Sep. 9 at 6:22 PM

0 · Reply

Cullousus Sep. 9 at 6:10 PM

$MDCX seems like r/s before a major run occurs i hope im wrong for shareholders sake.

0 · Reply

Steelcurtain04 Sep. 9 at 5:34 PM

$MDCX little humor while we wait

0 · Reply

dominantmets Sep. 9 at 4:53 PM

$MDCX calm before the storm !!! Get Ready!!!!!

2 · Reply

Putnik Sep. 9 at 4:43 PM

$MDCX come on already! Let’s go to .25

1 · Reply

spivak1976 Sep. 9 at 2:50 PM

$MDCX that volume is not impressive.

0 · Reply

memo_18 Sep. 9 at 2:18 PM

$MDCX Needs volume...

0 · Reply

JerryMcFire Sep. 9 at 2:15 PM

$MDCX

1 · Reply

memo_18 Sep. 9 at 2:09 PM

$MDCX

0 · Reply

Easttenn988 Sep. 9 at 2:08 PM

$MDCX come on now 🌋

1 · Reply

Ashmitch20 Sep. 9 at 1:36 PM

Volume at close yesterday was over 22M $MDCX

1 · Reply

Strindberg Sep. 9 at 12:38 PM

$MDCX The calm before the storm or what?

0 · Reply

FawkTrading Sep. 9 at 11:46 AM

$MDCX ping pong

0 · Reply

Strindberg Sep. 9 at 11:46 AM

$MDCX Shortable shares 1.4 million now!

1 · Reply

walfofwallstreet Sep. 9 at 11:15 AM

$MDCX 👇👇Huge upcoming 💎 Chart doesn’t lie 📊 massive $1 billion deal with $PFE confirmed news a new cancer drug 💎👇👇👇👇💎

2 · Reply

Market Cap	10.74M
Revenue (ttm)	0.00
Net Income (ttm)	-35.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-10.45

Volume	4,825,800
Avg Vol	4,134,868
Day's Range	N/A - N/A
Shares Out	63.18M
Stochastic %K	16%
Beta	0.12
Analysts	Strong Sell
Price Target	$4.47